- Home
- SEZL vs VCEL Comparison
SEZL vs VCEL Comparison
Compare SEZL & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SEZL | VCEL |
|---|---|---|
| Founded | 2016 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Financial Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 1.7B |
| IPO Year | 2023 | 1996 |
Fundamental Metrics
Financial Performance| Metric | SEZL | VCEL |
|---|---|---|
| Price | $65.69 | $32.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $114.20 | $58.50 |
| AVG Volume (30 Days) | ★ 697.9K | 485.5K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ 3.72 | 0.32 |
| Revenue | ★ $450,279,000.00 | $276,259,000.00 |
| Revenue This Year | $27.45 | $19.09 |
| Revenue Next Year | $26.94 | $17.96 |
| P/E Ratio | ★ $17.66 | $100.88 |
| Revenue Growth | ★ 66.08 | 16.45 |
| 52 Week Low | $25.00 | $29.24 |
| 52 Week High | $263.00 | $48.75 |
Technical Indicators
Market Signals| Indicator | SEZL | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | 35.04 |
| Support Level | $64.55 | $31.34 |
| Resistance Level | $70.80 | $38.48 |
| Average True Range (ATR) | 4.99 | 1.24 |
| MACD | -0.73 | -0.23 |
| Stochastic Oscillator | 2.91 | 20.11 |
Price Performance
Historical ComparisonAbout SEZL Sezzle Inc.
Sezzle Inc is a financing institution that offers technology-driven payment platform. It allows customers to split their purchase into four installments and pay over 6 weeks with only the first payment due at the time of purchase. Companies operations comprise one reportable segment, the majority of which derives revenue from payment processing platform in North America.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.